After gains of 12.2% this afternoon, Madrigal Pharmaceuticals shares are now trading at $273.22. Read below for the essential facts about this stock:
-
Madrigal Pharmaceuticals has logged a -2.8% 52 week change, compared to 31.5% for the S&P 500
-
MDGL has an average analyst rating of buy and is -19.2% away from its mean target price of $338.15 per share
-
Its trailing earnings per share (EPS) is $-20.0, which brings its trailing Price to Earnings (P/E) ratio to -13.7. The Health Care sector's average P/E ratio is 30.21
-
The company's forward earnings per share (EPS) is $-13.15 and its forward P/E ratio is -20.8
-
The company has a Price to Book (P/B) ratio of 13.4 in contrast to the Health Care sector's average P/B ratio is 4.08
-
The current ratio is currently 2.4, which consists in its liquid assets divided by any liabilities due within in the next 12 months